Science-backed

Leveraging emerging research and medications to reduce cravings and rebalance reward pathways.

Icon
Physician-led

Individual treatment plans from licensed providers with expertise in behavior change.

Icon
Personalized

Care tailored to your goals, your biology, and your life.

Icon
Private & Secure

100% online. Your privacy is protected at every step.

Modern life can become dopamine overload.

ALCOHOL
DRUGS
NICOTINE
PORN
SUGAR
SCROLLING

Different habits. Similar reward pathways. Most approaches treat the surface condition. Quel works on what's driving it—a dysregulated reward pathway—with modern therapeutics that quiet the noise and give you back agency.

Explore treatments
HOW IT WORKS

Simple. Private. Personalized.

1
Share what you want to change

No labels required.

2
Meet your clinician

A licensed provider reviews your history and goals.

3
Start your plan

Treatment may include GLP-1s and other evidence-informed therapies.*

4
Adjust over time

Care evolves with you.

A woman img
OUR FOUNDERS

Led by experts shaping the future of craving care.

Quel Health was founded by epidemiologist Marlene C. Lira, MPH, and physician-scientist Steven D. Klein, MD, PhD, bringing together expertise in telehealth, substance use, clinical care, and emerging GLP-1 therapies.* Together, they’re building a more accessible, private, and human-centered approach to dopamine health.

Icon
Marlene C. Lira, MPH
Co-Founder & Chief Executive Officer
Steven D. Klein, MD, PhD
Co-Founder & Chief Medical Officer
About Us
Available NationWide

Care that’s available where you live.

Quel currently provides virtual care in 41 states + Washington, D.C., with nationwide availability coming soon.

Check availability in your state

More clarity
Less noise

Private care for cravings, compulsive habits, and dopamine health. Start with a conversation — and gain a clearer understanding of what’s happening.
Icon
Private
100% confidential
Icon
Clinician-led
Licensed providers
Icon
Personalized
Built around you
Phone Mockups
*GLP-1 receptor agonists, including semaglutide (Wegovy®, Ozempic®), tirzepatide (Mounjaro®, Zepbound®), and orforglipron (Foundayo™), have not been approved by the FDA for substance use disorders, cravings, or behavioral compulsions. When used in this way, they are prescribed off-label based on clinical judgment and emerging research. Talk to your provider about the evidence, benefits, risks, and alternatives. These statements have not been evaluated by the FDA.